These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24135497)

  • 1. Propranolol prevents life-threatening arrhythmias in LQT3 transgenic mice: implications for the clinical management of LQT3 patients.
    Calvillo L; Spazzolini C; Vullo E; Insolia R; Crotti L; Schwartz PJ
    Heart Rhythm; 2014 Jan; 11(1):126-32. PubMed ID: 24135497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autonomic modulation and antiarrhythmic therapy in a model of long QT syndrome type 3.
    Fabritz L; Damke D; Emmerich M; Kaufmann SG; Theis K; Blana A; Fortmüller L; Laakmann S; Hermann S; Aleynichenko E; Steinfurt J; Volkery D; Riemann B; Kirchhefer U; Franz MR; Breithardt G; Carmeliet E; Schäfers M; Maier SK; Carmeliet P; Kirchhof P
    Cardiovasc Res; 2010 Jul; 87(1):60-72. PubMed ID: 20110334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reply to the Editor--Propranolol prevents life-threatening arrhythmias in LQT3 transgenic mice: implications for the clinical management of LQT3 patients.
    Schwartz PJ; Crotti L
    Heart Rhythm; 2014 Mar; 11(3):e1-2. PubMed ID: 24389231
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular biology of the long QT syndrome: impact on management.
    Priori SG; Napolitano C; Paganini V; Cantù F; Schwartz PJ
    Pacing Clin Electrophysiol; 1997 Aug; 20(8 Pt 2):2052-7. PubMed ID: 9272507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome.
    Shimizu W; Antzelevitch C
    J Am Coll Cardiol; 2000 Mar; 35(3):778-86. PubMed ID: 10716483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re-evaluating the efficacy of beta-adrenergic agonists and antagonists in long QT-3 syndrome through computational modelling.
    Ahrens-Nicklas RC; Clancy CE; Christini DJ
    Cardiovasc Res; 2009 Jun; 82(3):439-47. PubMed ID: 19264765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms by which SCN5A mutation N1325S causes cardiac arrhythmias and sudden death in vivo.
    Tian XL; Yong SL; Wan X; Wu L; Chung MK; Tchou PJ; Rosenbaum DS; Van Wagoner DR; Kirsch GE; Wang Q
    Cardiovasc Res; 2004 Feb; 61(2):256-67. PubMed ID: 14736542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left cardiac sympathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catecholaminergic polymorphic ventricular tachycardia and long QT syndrome.
    Schneider HE; Steinmetz M; Krause U; Kriebel T; Ruschewski W; Paul T
    Clin Res Cardiol; 2013 Jan; 102(1):33-42. PubMed ID: 22821214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific therapy based on the genotype and cellular mechanism in inherited cardiac arrhythmias. Long QT syndrome and Brugada syndrome.
    Shimizu W; Aiba T; Antzelevitch C
    Curr Pharm Des; 2005; 11(12):1561-72. PubMed ID: 15892662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial arrhythmogenesis in wild-type and Scn5a+/delta murine hearts modelling LQT3 syndrome.
    Dautova Y; Zhang Y; Sabir I; Grace AA; Huang CL
    Pflugers Arch; 2009 Jul; 458(3):443-57. PubMed ID: 19184093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paced electrogram fractionation analysis of arrhythmogenic tendency in DeltaKPQ Scn5a mice.
    Head CE; Balasubramaniam R; Thomas G; Goddard CA; Lei M; Colledge WH; Grace AA; Huang CL
    J Cardiovasc Electrophysiol; 2005 Dec; 16(12):1329-40. PubMed ID: 16403066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transmural dispersion of repolarization and arrhythmogenicity: the Brugada syndrome versus the long QT syndrome.
    Antzelevitch C; Yan GX; Shimizu W
    J Electrocardiol; 1999; 32 Suppl():158-65. PubMed ID: 10688320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of pacing and mexiletine on dispersion of repolarisation and arrhythmias in DeltaKPQ SCN5A (long QT3) mice.
    Fabritz L; Kirchhof P; Franz MR; Nuyens D; Rossenbacker T; Ottenhof A; Haverkamp W; Breithardt G; Carmeliet E; Carmeliet P
    Cardiovasc Res; 2003 Mar; 57(4):1085-93. PubMed ID: 12650887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of fatal arrhythmic events in long QT syndrome patients after syncope.
    Jons C; Moss AJ; Goldenberg I; Liu J; McNitt S; Zareba W; Qi M; Robinson JL
    J Am Coll Cardiol; 2010 Feb; 55(8):783-8. PubMed ID: 20170817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic lacunae and implications of an automated implantable cardioverter defibrillator implantation in a child with type 3 Long QT (LQT3) syndrome.
    Maddali MM; Kandachar PS; Al-Abri IA; Al-Yamani MI
    Ann Card Anaesth; 2022; 25(2):210-213. PubMed ID: 35417973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary Outcomes in Patients With Long QT Syndrome.
    Rohatgi RK; Sugrue A; Bos JM; Cannon BC; Asirvatham SJ; Moir C; Owen HJ; Bos KM; Kruisselbrink T; Ackerman MJ
    J Am Coll Cardiol; 2017 Jul; 70(4):453-462. PubMed ID: 28728690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triggers of ventricular tachyarrhythmias and therapeutic effects of nicorandil in canine models of LQT2 and LQT3 syndromes.
    Chinushi M; Kasai H; Tagawa M; Washizuka T; Hosaka Y; Chinushi Y; Aizawa Y
    J Am Coll Cardiol; 2002 Aug; 40(3):555-62. PubMed ID: 12142125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnosis, sudden death risk stratification, and treatment of main long QT syndrome molecular-genetic variants].
    Shkol'nikova MA; Kharlap MS; Il'darova RA; Bereznitskaia VV; Kalinin LA
    Kardiologiia; 2011; 51(5):50-61. PubMed ID: 21649595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous and transvenous implantable cardioverter defibrillator in high-risk long-QT syndrome type 3 associated with Val411Met mutation in SCN5A.
    Yokoyama Y; Aiba T; Ueda N; Nakajima K; Kamakura T; Wada M; Yamagata K; Ishibashi K; Inoue Y; Miyamoto K; Nagase S; Noda T; Yasuda S; Shimizu W; Kusano K
    J Cardiol Cases; 2020 Nov; 22(5):238-241. PubMed ID: 33133318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mexiletine Shortens the QT Interval in Patients With Potassium Channel-Mediated Type 2 Long QT Syndrome.
    Bos JM; Crotti L; Rohatgi RK; Castelletti S; Dagradi F; Schwartz PJ; Ackerman MJ
    Circ Arrhythm Electrophysiol; 2019 May; 12(5):e007280. PubMed ID: 31006312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.